- Report
- October 2024
- 187 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 194 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- October 2024
- 200 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- October 2024
- 196 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 89 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- June 2021
- 149 Pages
Global
From €2625EUR$2,750USD£2,199GBP
€5249EUR$5,500USD£4,398GBP
- Report
- October 2023
- 178 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- August 2022
- 133 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- November 2022
- 120 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 71 Pages
Global
From €3500EUR$3,929USD£3,035GBP
Soft tissue allografts are a type of medical device used in dermatology to treat a variety of skin conditions. Allografts are tissue transplants taken from a donor and transplanted into a patient. These allografts are typically used to treat skin conditions such as burns, chronic wounds, and ulcers. Allografts can also be used to reconstruct skin defects caused by trauma, surgery, or congenital defects.
The soft tissue allografts market is a rapidly growing segment of the medical device industry. It is driven by the increasing prevalence of skin conditions, the growing demand for minimally invasive treatments, and the availability of advanced technologies. The market is expected to continue to grow in the coming years due to the increasing demand for tissue grafts and the development of new technologies.
Some of the major companies in the soft tissue allografts market include MiMedx Group, Inc., Organogenesis, Inc., Integra LifeSciences Corporation, and LifeNet Health. Show Less Read more